- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Treatment resistant depression
- Meeting Date: July 2024
Esketamine – July 2024
Esketamine; Nasal spray solution 28 mg in 0.2 mL (2 actuations); Spravato® – July 2024 – December 2024
Public Summary Documents
Related Public Summary Documents
Last updated
30 May 2025
